Wyeth/Elan Submit Pharmacogenomics Study Report From Alzheimer’s Trial To FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
A gene expression study based on blood samples from a failed vaccine candidate trial could help develop other potential therapies, Wyeth says.
You may also be interested in...
United Neuroscience To Move Forward Alzheimer's Vaccine After Promising Phase IIa
It's early days yet and Alzheimer's is a field littered with failures, but the latest results for the vaccine UB-311 support advancing development.
United Neuroscience Hopes To Revive Vaccine Approach To Alzheimer’s
Emerging Company Profile: Dublin-based United Neuroscience, spun out of an animal vaccine maker, believes it can pick up and improve upon a vaccine approach to Alzheimer’s that was abandoned nearly two decades ago due to safety issues.
Elan Moving Alzheimer’s Candidate To Phase II Under Pact With Transition Therapeutics
Initial terms of the partnership include an unusual 70/30 split on development costs and eventual profits.